Genprex Reports Positive Clinical Trial Progress for Reqorsa Gene Therapy and New Biomarker Research Agreement

summarizeSummary

Genprex announced a new Sponsored Research Agreement with MD Anderson Cancer Center to study biomarkers for its Reqorsa Gene Therapy, alongside reporting positive safety and early efficacy data from its Acclaim-1 and Acclaim-3 clinical trials for lung cancer.

check_boxKey Events

• New Sponsored Research Agreement

  Genprex entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers (TROP2 and PTEN) that may predict patient response to Reqorsa® Gene Therapy for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This extends a long-standing collaboration.

• Acclaim-1 Clinical Trial Update

  The Phase 1/2 clinical trial (Acclaim-1) for NSCLC, combining Reqorsa® with Tagrisso®, showed Reqorsa® was generally well-tolerated with no dose-limiting toxicities. Early efficacy signals included prolonged progression-free survival in some patients, with one patient maintaining a partial response for approximately 42 months.

• Acclaim-3 Clinical Trial Update

  The Phase 1/2 clinical trial (Acclaim-3) for SCLC, combining Reqorsa® with Tecentriq®, also showed no dose-limiting toxicities. One patient achieved an unconfirmed partial remission after 24 cycles of therapy and continues treatment after more than 18 months.

auto_awesomeAnalysis

This filing provides crucial positive updates for Genprex, a micro-cap biotech company currently facing a potential Nasdaq delisting and seeking shareholder approval for a reverse stock split (as per the PRE 14A filed on 2026-04-17). The new Sponsored Research Agreement with MD Anderson Cancer Center, a long-standing partner, focuses on identifying biomarkers to optimize patient selection for Reqorsa® Gene Therapy in lung cancer. More significantly, the company reported encouraging safety and early efficacy signals from its ongoing Phase 1/2 Acclaim-1 and Acclaim-3 clinical trials, including prolonged progression-free survival and partial responses in some patients. These clinical advancements, particularly the long-term response in one Acclaim-1 patient (42 months), are vital for demonstrating the potential of their lead drug candidate and could help bolster investor confidence as the company navigates its financial and listing challenges.